The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. We performed a retrospective review of 67 patients newly diagnosed with multiple myeloma at Mayo Clinic and treated with a single regimen prior to stem cell transplantation between January of 2000 and September of 2001. Stem cells were collected from 24 patients who received thalidomide, 200 mg/day, with dexamethasone as initial therapy before stem cell collection. These patients were compared with 43 control patients seen during the same period who had received only one previous regimen before stem cell collection and transplantation. The cumulative thalidomide dose before stem cell collection was 17 000 mg over a median of four cycles (range, 2-7 cycles). The thalidomide and control groups were not significantly different in their baseline characteristics, number of stem cells collected, time to collection, or time to engraftment of neutrophils or platelet count of 50 000/ll. Time to platelet count of 20 000/ll was delayed by a median of 4 days (P ¼ 0.008), but platelet transfusion requirements did not differ (P ¼ 0.95). We concluded that thalidomide does not substantially affect peripheral cell mobilization or engraftment.
Summary:
The purpose of this study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. We performed a retrospective review of 67 patients newly diagnosed with multiple myeloma at Mayo Clinic and treated with a single regimen prior to stem cell transplantation between January of 2000 and September of 2001. Stem cells were collected from 24 patients who received thalidomide, 200 mg/day, with dexamethasone as initial therapy before stem cell collection. These patients were compared with 43 control patients seen during the same period who had received only one previous regimen before stem cell collection and transplantation. The cumulative thalidomide dose before stem cell collection was 17 000 mg over a median of four cycles (range, 2-7 cycles). The thalidomide and control groups were not significantly different in their baseline characteristics, number of stem cells collected, time to collection, or time to engraftment of neutrophils or platelet count of 50 000/ll. Time to platelet count of 20 000/ll was delayed by a median of 4 days (P ¼ 0.008), but platelet transfusion requirements did not differ (P ¼ 0.95). We concluded that thalidomide does not substantially affect peripheral cell mobilization or engraftment. Bone Marrow Transplantation (2003) 32, 587-592. doi:10.1038/sj.bmt.1704173 Keywords: hematopoietic stem cells; multiple myeloma; platelet engraftment; stem cell transplantation; thalidomide Multiple myeloma accounts for approximately 10% of all hematologic malignancies. It is an incurable disease, with 11 000 deaths occurring each year in the United States. The median survival of patients treated with conventional chemotherapy is approximately 3 years; with high-dose chemotherapy and autologous stem cell transplantation, complete remission rates are improved, as are disease-free and overall survival rates. 1 Bone marrow angiogenesis is increased in patients with myeloma and is a strong adverse prognostic indicator, correlating with the plasma cell labeling index and the disease stage. 2 Previously withdrawn from clinical use because of its severe teratogenicity, thalidomide has recently been reintroduced as a novel immunomodulatory and antiangiogenic therapy for patients with myeloma. In experimental models, thalidomide has inhibited angiogenesis and induced apoptosis of established neovasculature. 3 It has had marked activity in refractory myeloma 4, 5 and previously untreated disease. 6, 7 Known common side effects are sedation, fatigue, constipation, rash, and peripheral neuropathy. 4, 5 There are no data about its effect on hematopoietic stem cell number or function. Case reports 8 and anecdotal data have suggested that thalidomide may affect stem cell collection or engraftment. Since this novel agent is being used more frequently as an initial therapy for multiple myeloma, we wanted to address the effect of thalidomide on stem cell mobilization and engraftment.
Risk factors for impaired stem cell collection include previous exposure to melphalan, previous radiotherapy, extensive bone marrow plasma cell infiltration, and mobilization strategy. [9] [10] [11] [12] [13] Risk factors for delayed engraftment after autologous transplantation include an inadequate number of stem cells infused, previous exposure to an alkylating agent, increased patient age, serum beta 2 -microglobulin, previous radiotherapy, and the absence of postinfusion growth factor. [9] [10] [11] [12] [13] [14] [15] [16] The aim of our study was to determine the effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma.
Methods
Between January 2000 and September 2001, 24 patients with newly diagnosed myeloma were treated at Mayo Clinic (Rochester, MN, USA) with single-agent thalidomide or a combination of thalidomide and dexamethasone as initial therapy before stem cell mobilization and collection. For the five patients receiving an escalating dose of thalidomide, the starting dose was 200 mg/day taken orally as a single dose at bedtime. In the absence of adverse effects, the dose was increased by 200 mg every 2 weeks, to a maximum dose of 600 mg/day. The other 19 patients received 200 mg/day without dose escalation. Dexamethasone, 40 mg/day, was given on days 1-4, 9-12, and 17-20 of each month alternating with days 1-4. Serving as a control group were 43 consecutive patients who were evaluated during the same period and who received a single regimen (either single-agent dexamethasone or vincristine, adriamycin, and dexamethasone; one patient received melphalan and prednisone) before stem cell collection. Of note, one patient in the thalidomide group who had smoldering myeloma had received one cycle of vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone 14 months before starting treatment with thalidomide.
In both groups, stem cells were mobilized by administration of cyclophosphamide, 1.5 g/m 2 daily for each of 2 days, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF). In one control patient, insufficient stem cells were mobilized with cyclophosphamide and GM-CSF; 5 weeks later, administration of GM-CSF and granulocyte colony-stimulating factor (GCSF) allowed collection of a total of 3. , with samarium-153 ethylenediaminetetramethylenephosphonic acid (Sm-153 EDTMP). Only eight patients in the thalidomide group and 17 in the control group had all of their collected CD34 cells infused. Patients received GM-CSF from day 6 after stem cell transplantation and until neutrophil engraftment. Neutrophil engraftment was defined as the achievement of a sustained absolute neutrophil count of 500/ml. Two platelet engraftment levels were evaluated: a platelet count of 20 000/ml and a count of 50 000/ml. The date of engraftment was defined as the first day to reach a sustained platelet count of 20 000/ ml and a count of 50 000/ml, respectively, without platelet transfusions. For the patient who did not reach the platelet count of 20 000/ml and received the rest of his collected stem cells, the date of the second infusion was used as the censored end point. After reaching a platelet count of 20 000/ml, patients did not routinely have complete blood counts measured daily; therefore, a platelet count of 50 000/ml was collected as the first available sustained platelet count of 50 000/ml. The threshold for platelet transfusions in asymptomatic patients was approximately 10 000/ml. This retrospective study was approved by the Mayo Foundation Institutional Review Board and was conducted in accordance with the ethical guidelines mandated by the Declaration of Helsinki. All patients gave written consent for their records to be reviewed. All patients receiving thalidomide before mobilization were part of a prospective study and gave written consent for participation.
Statistical analysis
Data on thalidomide dose and treatment duration, days of peripheral blood stem cell collection, stem cell product, number of stem cells infused, number of transfusions, and time to engraftment were collected retrospectively. Differences between the thalidomide and control groups were analyzed by the w 2 test, Spearman correlation, or MannWhitney test, as appropriate. Time to engraftment was plotted according to the method of Kaplan and Meier. 17 Differences between curves were appraised by the GehanWilcoxon method. The Cox proportional hazards model was used for the multivariate analysis.
In the univariate analysis, factors evaluated for their influence on collection and engraftment included age, sex, maximum dose of thalidomide, cumulative dose of thalidomide, duration of thalidomide therapy, time between discontinuance of thalidomide and collection, number of bone marrow plasma cells at collection, serum beta 2 -microglobulin, level of M-protein before transplantation, plasma cell labeling index before transplantation, peripheral blood plasma cells and their percentage at mobilization, time from diagnosis to stem cell infusion, leukocyte count on the first day of leukapheresis, number of days between cyclophosphamide administration and first collection, total number of stem cells collected, number of days of collection, number of CD34 cells per collection (calculated by dividing the total number of CD34 cells collected by the number of collections), number of mononuclear cells per kilogram collected, disease status at transplantation, number of stem cells infused, early vs delayed transplantation, previous radiotherapy, response to chemotherapy before collection, and previous melphalan exposure and conditioning regimen used. The multivariate analysis was built in a stepwise fashion on the basis of the univariate findings.
Results

Patient characteristics
Patient characteristics are summarized in Table 1 . There was no significant difference between the thalidomide and control groups for any baseline characteristic. Patients in the thalidomide group were slightly older than the controls (60 vs 56 years old, respectively; P ¼ 0.08) and fewer had received radiation before transplantation. The median time from diagnosis of myeloma to transplantation was 6.4 months in the thalidomide group and 6.6 months in the control group. The median cumulative thalidomide dose before stem cell collection was 17 000 mg taken over a median of 4 months (range 2-7 cycles). Patients had their thalidomide discontinued at a median of 3.6 weeks (range 1.9-23.0 weeks) before infusion of cyclophosphamide for mobilization. Disease status at mobilization, number of CD34 cells infused at transplantation, and conditioning regimens did not differ between the two groups.
Stem cell collection data
The thalidomide and control groups did not differ significantly in number of CD34 cells collected or number of days of collection (Table 1) . However, patients in the thalidomide group were less likely to collect sufficiently in 1 day than were the controls (12 vs 35%, respectively; P ¼ 0.05). The total number of CD34 cells collected was not affected by previous duration of thalidomide, total dose of thalidomide, or duration between thalidomide cessation and mobilization. The number of collections was inversely proportional to the total number of CD34 cells collected (P ¼ 0.04); that is, patients with the highest total number of CD34 cells collected had a fewer number of collections. No factors affecting the number of CD34 cells collected were identified.
Hematopoietic reconstitution data
Times to engraftment in the thalidomide and control groups are shown in Table 2 . One patient in the control group was censored at 25 days after receiving a second stem cell infusion for failure of engraftment. There were no deaths before engraftment in either group. All patients were evaluable for graft function.
Factors shown on univariate analysis to affect engraftment are listed in Table 3 . Thalidomide had no effect on time to neutrophil engraftment (P ¼ 0.5; Figure 1 ) or time to an untransfused platelet count of 50 000/ml (P ¼ 0.1; Figure 2 ). Male sex adversely affected time to a platelet count of 50 000/ml. The thalidomide and control groups did not differ significantly (P ¼ 0.95) in number of red blood cell transfusions required (Table 2) . Time to an untransfused platelet count of 20 000/ml was approximately 4 days longer in the thalidomide group than in the controls (17.5 vs 13 days, respectively; P ¼ 0.008) (Figure 3 ). This delay in platelet engraftment did not result in a greater number of platelet transfusions; for both groups, the median number of platelet transfusions was 2 (P ¼ 0.9). This may be related to the fact that our threshold for platelet transfusions in asymptomatic patients was around 10 000/ml. On univariate analysis, the number of CD34 cells infused did not affect platelet engraftment, probably because all patients had a minimum infusion of at least 2.85 Â 10 6 /kg CD34 cells.
To test the robustness of our observation, we performed a separate analysis evaluating the subgroup of 56 patients whose conditioning regimen consisted solely of melphalan, 200 mg/m 2 . Overall results were no different (data not shown). In these 56 patients, the difference between the thalidomide and control groups in time to a platelet count of 20 000/ml persisted (18.5 vs 13 days, respectively; P ¼ 0.02). Only those factors reaching significance (Pp0.05) on univariate analysis were entered into the multivariate analysis.
On multivariate analysis, thalidomide was the only factor that affected time to platelet count of 20 000/ml (P ¼ 0.01; 95% CI 0.3-0.9). 
Discussion
Thalidomide was first used as a sedative and then as an antiemetic in pregnancy before its teratogenic effect was observed and it was withdrawn from use. It was later approved for the treatment of erythema nodosum leprae and cachexia from acquired immunodeficiency syndrome, aphthous ulcers in Behc¸et disease, and treatment of chronic graft-versus-host disease. 3, 18 Owing to its possible antiangiogenic properties, thalidomide has been recommended for relapsed multiple myeloma. 4, 5, 19, 20 Thalidomide induces a clinical response in approximately one-third of patients with multiple myeloma whose disease is refractory to conventional and high-dose therapy. Benefit has been demonstrated as first-line therapy. 5, 18, 21 The mechanism of action of thalidomide in myeloma is unknown. It acts both on immunomodulation and angiogenesis, affecting the expression of cell surface adhesion molecules 2, 18, [21] [22] [23] and blocking the action of angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor. However, it is not yet known whether the immunomodulatory or antiangiogenic effects of thalidomide lead to its activity in myeloma or whether these affect stem cell mobilization and engraftment.
As used in this study, thalidomide did not appear to significantly affect the ability to mobilize CD34 cells, although patients receiving thalidomide were less likely to collect in 1 day compared to the control group. Desikan and Jagannath 8 recently reported a patient in whom stem cell procurement was difficult when thalidomide was continued during stem cell mobilization. The authors speculated that an impaired ability to mobilize stem cells in the presence of thalidomide may be related to thalidomide's modulation of adhesion molecules in the bone marrow stroma. [24] [25] [26] [27] Several factors have been identified as adversely affecting engraftment, including inadequate stem cell dose, previous exposure to an alkylating agent, increasing patient age, serum beta 2 -microglobulin, previous radiotherapy, and lack of growth factor use after infusion. [9] [10] [11] [12] [13] [14] [15] [16] 28 In our study, early platelet engraftment of 20 000/ml was affected by previous thalidomide use. The absence of the same observation on the time to reach a platelet count of 50 000/ml may reflect the wider intervals used in monitoring the platelet count after it reaches a safe clinical level and therefore may not reflect platelet engraftment kinetics.
Although this is a small retrospective study and needs to be verified in larger cohorts, our data demonstrate that thalidomide, used for a limited time and discontinued approximately 3-4 weeks before attempted mobilization, does not substantially affect peripheral stem cell mobilization or engraftment, but delays early platelet engraftment of 20 000/ml.
